Exudative Age-Related Macular Degeneration: The Advent of Anti-VEGF Agents

Thomas A. Ciulla, MD, MBA


September 18, 2023

Thomas A. Ciulla, MD, MBA, recalls a period during training at Harvard Medical School in which the application of lasers was standard treatment for exudative age-related macular degeneration (AMD), despite its limited therapeutic effect and often costly benefit.

Describing a certain patient's situation that was marked by especially challenging circumstances, Dr Ciulla extols the arrival of anti-VEGF therapies, which in this case resulted not only in halting the disease course, but in a partial restoration of lost vision. Looking ahead, Dr. Ciulla notes that there is an enduring need for improved modes of treatment to ensure the kind of continuous care that will secure the best outcomes for patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.